Milestone Pharmaceuticals Inc. (MIST) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.73 (-7.55% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MIST ranks #350 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMN (ProMIS Neurosciences Inc. (ON)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $99.4M) and GNLX (Genelux Corporation) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $95.0M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).
Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $0 in revenue, -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 46 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
While MIST currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.89) and Max Pain ($0.77) forces dealer call-delta covering toward $3.21.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Milestone Pharmaceuticals Inc. (MIST) dropped -7.55% to $0.73, trading at 4% of its 52-week range ($0.63 – $3.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular me
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular me
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MIST today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MIST. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Milestone Pharmaceuticals Inc. (MIST) ranks #350 by composite RQD confidence (47/100, grade D) and #663 by equity capitalization ($98.3M). Within this direct 5-issuer industry benchmark cohort, MIST leads on earnings valuation at N/A trailing P/E, while MIST leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MIST currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MIST
ACTIVE
Milestone Pharmaceuticals Inc. | D | 47/100 | — | — | -35.0% | -7.55% | $98.3M | Benchmark Subject |
| PMN ProMIS Neurosciences Inc. (ON) | D- | 40/100 | — | — | -35.0% | -70.13% | $99.4M | /pmn-vs-mist → |
| GNLX Genelux Corporation | E | 29/100 | — | — | -35.0% | -0.95% | $95.0M | /gnlx-vs-mist → |
| PMVP PMV Pharmaceuticals Inc. | D | 45/100 | — | — | -35.0% | -2.96% | $101.9M | /pmvp-vs-mist → |
| COYA Coya Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -9.30% | $93.4M | /coya-vs-mist → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Milestone Pharmaceuticals Inc. (MIST) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$63.1K, operating cash flow of -$49.0M, and free cash flow of -$49.3M (-70.8% YoY). On the balance sheet, MIST closed FY2025 with $113.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$63.1K | -$49.0M | -$49.3M | $113.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$41.5K | -$28.8M | -$28.9M | $75.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$59.7K | -$46.4M | -$46.4M | — | — |
As of 2026-11-02, Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.73 (-7.55% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MIST ranks #350 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MIST carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PMN (ProMIS Neurosciences Inc. (ON)) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $99.4M) and GNLX (Genelux Corporation) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $95.0M). Among the 5-stock peer group, MIST leads on earnings multiple (N/A) while MIST leads on capital efficiency (-35.0% ROIC).
Per MIST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001408443), Milestone Pharmaceuticals Inc. generated $0 in revenue, -$63.1K in net income, and -$49.3M in free cash flow against $113.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MIST last traded at $0.73 (-7.55% on volume of 730,167 shares), positioning the stock -17.98% below its 50-day simple moving average ($0.89) and -46.72% below its 200-day simple moving average ($1.37). Across its 52-week range of $0.63 to $3.06, MIST sits at the 4.1% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.82).
Why MIST Stock dropped -7.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, MIST scores 47 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Taken together, the rating frames MIST as a high-risk, cash-burning name. The key valuation tradeoff is that a market cap of $98.3M against negative operating income leaves little margin for execution error. Upside would depend on catalysts converting into cash flow, while the distribution warning and weak Piotroski reading point to downside risk if sentiment deteriorates.
Milestone Pharmaceuticals Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. The source data does not describe its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of the three periods shown, indicating no revenue recognition in the reported data. Market capitalization is $0.1B per the profile.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-62.1M | $-0.1M | N/A | $-49.3M | $73.0M | N/A |
| FY 2024 | $0.0M | $-42.1M | $-0.0M | N/A | $-28.9M | $25.3M | N/A |
| FY 2023 | $0.0M | $-61.1M | $-0.1M | N/A | $-46.4M | N/A | N/A |
Per the SEC financials, operating losses were $-62.1M in FY 2025 and $-42.1M in FY 2024, and free cash flow was negative in every period shown. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity at 0.5. Reported cash rose from $25.3M in FY 2024 to $73.0M in FY 2025 per the SEC financials.
Per the news feed, the listing-compliance items are the most consequential for a sub-$1 stock. The Cardamyst item carries a RED light and points to downward expectation revisions. The first-European-patient trial enrollment is the only GREEN clinical item in the feed.
Per the butterfly supply-chain graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Milestone Pharmaceuticals Inc. (MIST) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Milestone Pharmaceuticals Inc. (MIST) market action, institutional positioning, and fundamental catalysts.
Welcome to the MIST (Milestone Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on MIST, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Milestone Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on MIST, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.79 (52-wk range $0.69 - $0.86), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).